Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
0.25% EISO mouth rinse
- Development stage
- Unknown
- Lead developer
- TFS Corporation
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
0.25% EISO mouth rinse is an investigational botanical drug candidate developed by Santalis Pharmaceuticals for the prevention and treatment of radiation-induced oral mucositis in patients with head and neck cancer. The formulation consists of 0.25% (w/w) Rectified East Indian Sandalwood Oil (EISO) as the active ingredient in an alcohol-free mouth rinse. EISO possesses anti-inflammatory properties, which are believed to be mediated through the inhibition of phosphodiesterases (PDE), particularly PDE4 and PDE7, thereby suppressing the activation of nuclear factor kappa B (NF-kB) and the subsequent production of pro-inflammatory cytokines and chemokines. The drug has been evaluated in an open-label, proof-of-concept Phase 2 clinical trial (NCT02399228).
- Other names
- 0.25% East Indian Sandalwood Oil mouth rinseEISO mouth rinseEast Indian Sandalwood Oil mouth rinseSAO mouth rinseSandalwood Album Oil mouth rinse
02
Targets
NF-κBPDE4 (Phosphodiesterase 4A1)PDE7A (Phosphodiesterase 7A)
Beyond the preview
Go deeper on 0.25% EISO mouth rinse.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 0.25% EISO mouth rinse.